"Disease"	"Gene"	"Variant"	"Description"	"Effect"	"Association_1"	"Therapeutic.context_1"	"Status_1"	"Evidence_1"	"PMID_1"	"Association_2."	"Therapeutic.context_2"	"Status_2"	"Evidence_2"	"PMID_2"	"Association_3."	"Therapeutic.context_3"	"Status_3"	"Evidence_3"	"PMID_3"	"Association_4."	"Therapeutic.context_4"	"Status_4"	"Evidence_4"	"PMID_4"	"Association_5."	"Therapeutic.context_5"	"Status_5"	"Evidence_5"	"PMID_5"	"Association._6"	"Therapeutic.context_6"	"Status_6"	"Evidence_6"	"PMID_6"	"Association_7."	"Therapeutic.context_7"	"Status_7"	"Evidence_7"	"PMID_8"	"Association_8."	"Therapeutic.context_8"	"Status_8"	"Evidence_8"	"PMID_8.1"
"chronic_myeloid_leukemia"	"ABL1"	"F359V/C/I, Y253H, E255K/V"	"missense mutation"	"gain-of-function"	"response"	" dasatinib, bosutinib, ponatinib"	"NCCN guidelines"	"consensus"	"21562040"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"ABL1"	"F359V/C/I, Y253H, E255K/V"	"missense mutation"	"gain-of-function"	"response"	" dasatinib, ponatinib"	"NCCN guidelines"	"consensus"	"NCCN"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"chronic_myeloid_leukemia"	"ABL1"	"T315A, F317L/V/I/C"	"missense mutation"	"gain-of-function"	"response"	" nilotinib, bosutinib, ponatinib"	"NCCN guidelines"	"consensus"	"21562040"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"ABL1"	"T315A, F317L/V/I/C, V299L"	"missense mutation"	"gain-of-function"	"response"	" nilotinib, ponatinib"	"NCCN guidelines"	"consensus"	"NCCN"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"chronic_myeloid_leukemia"	"ABL1"	"V299L"	"missense mutation"	"gain-of-function"	"response"	" nilotinib, ponatinib"	"NCCN guidelines"	"consensus"	"21562040"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"ABL1"	"T315I"	"missense mutation"	"gain-of-function"	"response"	" ponatinib"	"NCCN guidelines"	"consensus"	"NCCN"	"response"	"AURK inhibitors + BCR-ABL1 inhibitors"	"case report"	"emerging"	"22772060"	"response"	"axitinib"	"case report"	"emerging"	"25686603"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"chronic_myeloid_leukemia"	"ABL1"	"T315I"	"missense mutation"	"gain-of-function"	"response"	" ponatinib"	"NCCN guidelines"	"consensus"	"21562040"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"AR"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"abiraterone"	"early trials"	"emerging"	"26537258"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"AR"	"L702H, T878A"	"missense mutation"	"gain-of-function"	"resistance"	"abiraterone"	"early trials"	"emerging"	"26537258"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"ERBB2"	"A775_G776insYVMA, G776delinsVC, V659E, S310F"	"mutation"	"gain-of-function"	"response"	"ado-trastuzumab emtansine"	"early trials"	"emerging"	"ASCO 2017 (abstr 8510)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"ERBB2"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"afatinib"	"case report"	"emerging"	"27044931"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"NRG1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"afatinib"	"case report"	"emerging"	"AACR 2016 (abstr 2631)"	"sensitivity"	"lapatinib"	"preclinical"	"emerging"	"24727320"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"ERBB3"	"G284R, V104M, R103G"	"missense mutation"	"gain-of-function"	"response"	"afatinib"	"case report"	"emerging"	"27044931"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"ERBB3"	"G284R, R103G"	"missense mutation"	"gain-of-function"	"response"	"afatinib  "	"case report"	"emerging"	"ASCO 2015 (abstr e15516)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"PIK3CB"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"AKT inhibitor, mTORC1/2 inhibitors"	"preclinical"	"emerging"	"23619167"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"pancreatic"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"AKT inhibitors"	"case report"	"emerging"	"22025163"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"AKT1"	"E17K"	"missense mutation"	"gain-of-function"	"sensitivity"	"AKT inhibitors"	"preclinical"	"emerging"	"21464312, 17611497, 23134728"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"PIK3R1"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"AKT inhibitors"	"preclinical"	"emerging"	"23166678"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"AKT2"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"allosteric AKT inhibitors"	"preclinical"	"emerging"	"ENA 2014 (abstr 373)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"AKT1"	"E17K"	"missense mutation"	"gain-of-function"	"sensitivity"	"allosteric AKT inhibitors"	"preclinical"	"emerging"	"21464312, 17611497"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"TOP2A"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"anthracyclines"	"late trials"	"emerging"	"22864769"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"SERPINB3"	"mut"	"mutation"	"loss-of-function"	"response"	"anti-CTLA4 mAbs"	"early trials"	"emerging"	"27668655"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"ERBB2"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"anti-EGFR mAbs"	"early trials"	"emerging"	"22586653, 23348520"	"response"	"trastuzumab + lapatinib (in KRAS wt)"	"early trials"	"emerging"	"27108243"	"response"	"trastuzumab emtansine"	"case report"	"emerging"	"http://ascopubs.org/doi/full/10.1200/PO.16.00055"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"ERBB3"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"anti-EGFR mAbs"	"early trials"	"emerging"	"25520391"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"IGF2"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"anti-EGFR mAbs"	"early trials"	"emerging"	"25632036"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"MET"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"anti-EGFR mAbs"	"early trials"	"emerging"	"23729478"	"response"	"cabozantinib + panitumumab"	"case report"	"emerging"	"ENA 2015 (abstract A52)"	"sensitivity"	"BCL2 inhibitors"	"preclinical"	"emerging"	"27397505"	"resistance"	"vemurafenib and panitumumab (in BRAF V600E mutated)"	"case report"	"emerging"	"27325282"	"response"	"crizotinib and vemurafenib (in BRAF V600E mutated)"	"case report"	"emerging"	"27325282"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"KRAS"	"any"	"mutation"	"gain-of-function"	"resistance"	"anti-EGFR mAbs"	"preclinical"	"emerging"	"22614881, 22290393"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"MAP2K1"	"unknown"	"mutation"	"gain-of-function"	"resistance"	"anti-EGFR mAbs"	"case report"	"emerging"	"26030179"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"resistance"	"anti-EGFR mAbs"	"late trials"	"emerging"	"21163703, 19398573"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"AREG"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"anti-EGFR mAbs"	"early trials"	"emerging"	"19738126, 26341080"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"EGFR"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"anti-EGFR mAbs"	"late trials"	"emerging"	"18794099, 17664472"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"EREG"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"anti-EGFR mAbs"	"early trials"	"emerging"	"19738126, 26341080"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ESR1"	"ERS1-YAP1 rearrangement"	"fusion gene"	"gain-of-function"	"resistance"	"anti-estrogens"	"preclinical"	"emerging"	"24055055"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ESR1"	"E380Q, codons 537, 538, L536, P535H"	"missense mutation"	"gain-of-function"	"resistance"	"anti-estrogens"	"early trials"	"emerging"	"24185512, 24185510, 24398047, 24185512, 24185510, 24185512"	", response"	", novel estrogen receptor degrader"	", early trials"	", emerging"	", AACR 2015 (abstr CT231)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MCL1"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"anti-tubulin agents"	"preclinical"	"emerging"	"21368834"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"FBXW7"	"any"	"mutation or copy number loss"	"loss-of-function"	"resistance"	"anti-tubulin agents"	"preclinical"	"emerging"	"21368834"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"GATA3"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"aromatase inhhibitors"	"preclinical"	"emerging"	"24758297"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"response"	"aspirin in adjuvant setting"	"late trials"	"emerging"	"23094721"	"resistance"	"cetuximab "	"late trials"	"emerging"	"19223544, 20619739"	"sensitivity"	"PI3K pathway inhibitors (alone or in combination)"	"preclinical"	"emerging"	"23475782, 22392911 "	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"AKT3"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"ATP-competitive AKT inhibitors"	"preclinical"	"emerging"	"22722202"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"ATM"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"ATR inhibitors"	"case report"	"emerging"	"ENA 2015 (abstract A48)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"ARID1A"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"ATR inhibitors"	"preclinical"	"emerging"	"27958275"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"PML-RARA"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"ATRA + arsenic trioxide"	"FDA-approved"	"consensus"	"FDA"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"AURKA"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"AURK inhibitors"	"preclinical"	"emerging"	"22302096"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"AURKA"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"AURK inhibitors"	"preclinical"	"emerging"	"22389870"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lymphoma"	"BCL2"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"BCL2 inhibitors"	"preclinical"	"emerging"	"22649144"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"FOXA1"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"BCL2 inhibitors"	"preclinical"	"emerging"	"27397505"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"NUT_midline_carcinoma"	"BRD4"	"BRD4-NUT fusion"	"rearrangement"	"gain-of-function"	"response"	"BET inhibitors"	"case report"	"emerging"	"ENA 2015 (abstract A49)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloma"	"MYC"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"BET inhibitors"	"preclinical"	"emerging"	"21889194"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"CRLF2"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"BET inhibitors"	"preclinical"	"emerging"	"22904298"	"sensitivity"	"mTOR inhibitors"	"preclinical"	"emerging"	"22955920"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"FAT1"	"mut"	"mutation"	"loss-of-function"	"sensitivity"	"BET inhibitors"	"preclinical"	"emerging"	"27397505"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"SUZ12"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"BET inhibitors"	"preclinical"	"emerging"	"25119042"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"schwannoma"	"NF2"	"any"	"mutation"	"loss-of-function"	"response"	"bevacizumab"	"early trials"	"emerging"	"22805104"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"AR"	"W741"	"missense mutation"	"gain-of-function"	"resistance"	"bicalutamide"	"preclinical"	"emerging"	"12517791"	"sensitivity"	"enzalutamide, ARN-509"	"preclinical"	"emerging"	"23779130"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"CDH1"	"mut"	"mutation"	"loss-of-function"	"sensitivity"	"bicalutamide"	"preclinical"	"emerging"	"27397505"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_squamous"	"MLL2"	"mut"	"mutation"	"loss-of-function"	"sensitivity"	"bicalutamide"	"preclinical"	"emerging"	"27397505"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloma"	"FGFR3"	"Y373C"	"missense mutation"	"gain-of-function"	"resistance"	"bortezomib"	"preclinical"	"emerging"	"19331127, 21273588"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"22869148"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloma"	"FGFR3"	"K650"	"missense mutation"	"gain-of-function"	"sensitivity"	"bortezomib"	"preclinical"	"emerging"	"19331127, 21273588"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"16091734, 20439987"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"MAP2K2"	"Q60P"	"missense mutation"	"gain-of-function"	"resistance"	"BRAF + MEK inhibitors"	"case report"	"emerging"	"24265154"	"sensitivity"	"ERK inhibitors"	"preclinical"	"emerging"	"24265154"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"BRAF"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"BRAF inhibitor + MEK inhibitor"	"case report"	"emerging"	"ASCO 2017 (abstr 9072)"	"sensitivity"	"sorafenib, MEK inhibitors"	"preclinical"	"emerging"	"24727320"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"KRAS"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"BRAF inhibitor + MEK inhibitor/anti-EGFR mAb"	"case report"	"emerging"	"ENA 2014 (abstr 428)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"ARAF"	"unknown"	"mutation"	"gain-of-function"	"resistance"	"BRAF inhibitor + MEK inhibitor/anti-EGFR mAb"	"case report"	"emerging"	"ENA 2014 (abstr 428)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"MITF"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"BRAF inhibitors"	"case report"	"emerging"	"24265153"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"AKT1"	"Q79K"	"missense mutation"	"gain-of-function"	"resistance"	"BRAF inhibitors"	"preclinical"	"emerging"	"24265152"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"MAP2K1"	"P124"	"missense mutation"	"gain-of-function"	"resistance"	"BRAF inhibitors"	"early trials"	"emerging"	"25370473"	"sensitivity"	"MEK inhibitors, ERK inhibitors"	"preclinical"	"emerging"	"25370473"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BRAF"	"V600R"	"missense mutation"	"gain-of-function"	"response"	"BRAF inhibitors"	"early trials"	"emerging"	"23237741"	"response"	"MEK inhibitors"	"case report"	"emerging"	"23248257"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"BRAF"	"V600E"	"missense mutation"	"gain-of-function"	"response"	"BRAF inhibitors"	"case report"	"emerging"	"22608338"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"19018267"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"BRAF"	"V600E"	"missense mutation"	"gain-of-function"	"sensitivity"	"BRAF inhibitors"	"preclinical"	"emerging"	"22038996, 22586120"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"resistance"	"BRAF inhibitors in BRAF mutant tumor"	"early trials"	"emerging"	"http://ascopubs.org/doi/abs/10.1200/PO.16.00054"	"resistance"	"MEK inhibitors in BRAF mutant tumors"	"preclinical"	"emerging"	"23039341"	"resistance"	"PD1 inhibitors"	"early trials"	"emerging"	"26645196"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"MAP2K1"	"P124S, I111S"	"missense mutation"	"gain-of-function"	"response"	"BRAF inhibitors in BRAF mutant tumor"	"case report"	"emerging"	"22588879"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"RAC1"	"P29S"	"missense mutation"	"gain-of-function"	"resistance"	"BRAF inhibitors in BRAF mutant tumors"	"case report"	"emerging"	"25056119"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"RAF1"	"S257P, P261P, G361A"	"missense mutation"	"gain-of-function"	"resistance"	"BRAF inhibitors in BRAF mutant tumors"	"preclinical"	"emerging"	"23737487"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"MAP2K1"	"P124L, C121S"	"missense mutation"	"gain-of-function"	"resistance"	"BRAF inhibitors, MEK inhibitors"	"case report"	"emerging"	"19915144, 21383288"	", sensitivity"	", novel MEK inhibitors"	", preclinical"	", emerging"	", 24448821"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"MAP2K2"	"V35M, L46F, N126D, C125S"	"missense mutation"	"gain-of-function"	"resistance"	"BRAF inhibitors, MEK inhibitors"	"preclinical"	"emerging"	"24265153"	"sensitivity"	"ERK inhibitors"	"preclinical"	"emerging"	"24265153"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ALK"	"E1408V"	"missense mutation"	"gain-of-function"	"response"	"brigatinib"	"case report"	"emerging"	"ASCO 2017 (abstr 9065)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"RET"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"cabozantinib, vandetanib, sunitinib"	"early trials"	"emerging"	"28447912"	"response"	"nintedanib"	"case report"	"emerging"	"26787234"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thyroid"	"RET-PTC1"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"cabozantinib, vandetanib, sunitinib"	"preclinical"	"emerging"	"21470995"	"sensitivity"	"RET inhibitors"	"preclinical"	"emerging"	"23056499"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CCNE1"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"CDK2 inhibitors"	"preclinical"	"emerging"	"22471707"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CDKN2C"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"CDK2 inhibitors"	"preclinical"	"emerging"	"22471707, 22997239"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CDKN1A"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"CDK2/4 inhibitors"	"preclinical"	"emerging"	"22471707, 22997239"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CDKN1B"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"CDK2/4 inhibitors"	"preclinical"	"emerging"	"22471707"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"liposarcomas"	"CDK4"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"CDK4 inhibitors (tumors with RB expression)"	"early trials"	"emerging"	"23569312"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"CCND1"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"CDK4/6 inhibitors"	"case report"	"emerging"	"ASCO 2014 (abstr 2528)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"CDKN2A"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"CDK4/6 inhibitors"	"case report"	"emerging"	"ASCO 2013 (abstr 2500)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CCND1"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"CDK4/6 inhibitors"	"preclinical"	"emerging"	"22471707"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CCND2"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"CDK4/6 inhibitors"	"preclinical"	"emerging"	"22471707"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CCND3"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"CDK4/6 inhibitors"	"preclinical"	"emerging"	"22471707"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CDKN2A"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"CDK4/6 inhibitors"	"preclinical"	"emerging"	"22471707"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"CDKN2A"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"CDK4/6 inhibitors"	"preclinical"	"emerging"	"22586120, 22711607"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CDKN2B"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"CDK4/6 inhibitors"	"preclinical"	"emerging"	"22471707"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"CDKN2B"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"CDK4/6 inhibitors"	"preclinical"	"emerging"	"22711607"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"CDKN2C"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"CDK4/6 inhibitors"	"preclinical"	"emerging"	"22711607"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"TP53"	"mut"	"mutation"	"loss-of-function"	"resistance"	"CDK4/CDK6 inhibitor abemaciclib"	"early trials"	"emerging"	"27217383"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CDK6"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"CDK6 inhibitors"	"preclinical"	"emerging"	"22471707"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"KRAS"	"G13D"	"missense mutation"	"gain-of-function"	"no response"	"cetuximab"	"late trials"	"emerging"	"27114605"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"EGFR"	"S464L, G465R, I491M, R451C, K467T, S492R"	"missense mutation"	"gain-of-function"	"resistance"	"cetuximab"	"preclinical, case report"	"emerging"	"25623215, 25623215, 26888827, 22270724"	", sensitivity, response"	", panitumumab"	", preclinical, case report"	", emerging"	", 25623215, 22270724"	", response"	", novel anti-EGFR mAbs"	", early trials"	", emerging"	", 25962717"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"EGFR"	"P546S"	"missense mutation"	"gain-of-function"	"response"	"cetuximab"	"case report"	"emerging"	"23578570"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"EGFR"	"P753S"	"missense mutation"	"gain-of-function"	"response"	"cetuximab + sirolimus"	"case report"	"emerging"	"24934779"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"BRAF"	"V600"	"missense mutation"	"gain-of-function"	"resistance"	"cetuximab, panitumumab"	"late trials"	"emerging"	"20619739, 21163703, 23325582 "	"no response"	"vemurafenib"	"early trials"	"emerging"	"26460303"	"response"	"dabrafenib + trametinib"	"early trials"	"emerging"	"26392102"	"response"	"BRAF inhibitors + MEK inhibitors + anti-EGFR mAbs"	"early trials"	"emerging"	"ASCO 2014 (abstr 3515), ASCO 2015 (abstr 103)"	"response"	"BRAF inhibitors + anti-EGFR mAbs +/- PI3K pathway inhibitors"	"early trials"	"emerging"	"28363909"	"response"	"irinotecan + vemurafenib + cetuximab"	"early trials"	"emerging"	"27729313"	""	""	""	""	""	""	""	""	""	""
"colorectal"	"EGFR"	"G465R"	"missense mutation"	"gain-of-function"	"resistance"	"cetuximab, panitumumab"	"case report"	"emerging"	"26059438, 26888827"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"KRAS"	"any"	"mutation"	"gain-of-function"	"resistance"	"cetuximab, panitumumab"	"FDA-rejected"	"consensus"	"FDA"	"sensitivity"	"mTOR inhibitors + BH3 mimetics"	"preclinical"	"emerging"	"24163374"	"sensitivity"	"anti-EGFR mAbs + MEK inhibitors"	"preclinical"	"emerging"	"24553387"	"sensitivity"	"MEK inhibitors + PI3K pathway inhibitors"	"preclinical"	"emerging"	"22392911"	"sensitivity"	"MEK inhibitors + BCL-XL inhibitors"	"preclinical"	"emerging"	"23245996"	"sensitivity"	"MEK inhibitors + IGF1R inhibitors"	"preclinical"	"emerging"	"24045180"	"sensitivity"	"ERK inhibitors"	"preclinical"	"emerging"	"23614898"	""	""	""	""	""
"colorectal"	"NRAS"	"any"	"mutation"	"gain-of-function"	"resistance"	"cetuximab, panitumumab"	"NCCN guidelines"	"consensus"	"24024839, 20619739, 23325582"	"sensitivity"	"MEK inhibitors +/- PI3K pathway inhibitors"	"preclinical"	"emerging"	"23274911, 22392911"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"KRAS"	"wild type"	"no mutation"	"not applicable"	"response"	"cetuximab, panitumumab"	"FDA-approved"	"consensus"	"FDA"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"germ-cell tumor"	"MDM2"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"cisplatin"	"early trials"	"emerging"	"27646943"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"germ-cell tumor"	"TP53"	"mut"	"mutation"	"loss-of-function"	"resistance"	"cisplatin"	"early trials"	"emerging"	"27646943"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"ATM"	"any"	"mutation"	"loss-of-function"	"response"	"cisplatin"	"early trials"	"emerging"	"26238431"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"ERCC2"	"any"	"mutation"	"loss-of-function"	"response"	"cisplatin"	"early trials"	"emerging"	"25096233"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"FANCC"	"any"	"mutation"	"loss-of-function"	"response"	"cisplatin"	"early trials"	"emerging"	"26238431"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"RB1"	"any"	"mutation"	"loss-of-function"	"response"	"cisplatin"	"early trials"	"emerging"	"26238431"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"ERCC4"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"cisplatin"	"preclinical"	"emerging"	"25634215"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"ERCC6"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"cisplatin"	"preclinical"	"emerging"	"25634215"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"PDGFRA"	"V658A"	"missense mutation"	"gain-of-function"	"sensitivity"	"crenolanib"	"preclinical"	"emerging"	"24132921"	"resistance"	"imatinib"	"preclinical"	"emerging"	"24132921"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"ALK"	"F1174L"	"missense mutation"	"gain-of-function"	"reduced sensitivity"	"crizotinib"	"preclinical"	"emerging"	"22072639"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MET"	"Y1230C, Y1235D"	"missense mutation"	"gain-of-function"	"reduced sensitivity"	"crizotinib"	"preclinical"	"emerging"	"17483355"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ALK"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"crizotinib"	"case report"	"emerging"	"22277784"	"response"	"brigatinib"	"case report"	"emerging"	"ASCO 2017 (abstr 9065)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ALK"	"1151Tins"	"insertion mutation"	"gain-of-function"	"resistance"	"crizotinib"	"case report"	"emerging"	"22277784"	"response"	"ceritinib"	"FDA-approved"	"consensus"	"24670165"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"inflammatory_myofibroblastic_tumor"	"ALK"	"G1128A"	"missense mutation"	"gain-of-function"	"resistance"	"crizotinib"	"case report"	"emerging"	"http://ascopubs.org/doi/full/10.1200/PO.17.00015"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ALK"	"L1196M, L1152R, C1156Y, F1174L, G1202R, S1206Y, G1269A"	"missense mutation"	"gain-of-function"	"resistance"	"crizotinib"	"case report"	"emerging"	"22277784"	"response, , sensitivity"	"ceritinib, , lorlatinib, novel ALK inhibiors"	"FDA-approved, , preclinical"	"consensus, , emerging"	"24670165, 24327273, , 27401242, 24327273, 24670165"	"response, "	"brigatinib, "	"case report, "	"emerging, "	"ASCO 2017 (abstr 9065), "	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ROS1"	"G2032R"	"missense mutation"	"gain-of-function"	"resistance"	"crizotinib"	"case report"	"emerging"	"23724914, 25688157"	"sensitivity"	"cabozantinib"	"preclinical"	"emerging"	"25351743"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"MET"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"crizotinib"	"case report"	"emerging"	"22162573"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"MET"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"crizotinib"	"early trials"	"emerging"	"ASCO 2014 (abstr 8001), ASCO 2015 (abstr 2595)"	"resistance"	"EGFR TKIs (EGFR mut disease)"	"early trials"	"emerging"	"ASCO 2015 (abstr 8089)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"inflammatory_myofibroblastic_tumor"	"ALK"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"crizotinib"	"case report"	"emerging"	"20979472"	"response"	"ceritinib"	"case report"	"emerging"	"27742657"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lymphoma"	"ALK"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"crizotinib"	"early trials"	"emerging"	"24491302"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thyroid"	"ALK"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"crizotinib"	"case report"	"emerging"	"24687827"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"MET"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"crizotinib"	"case report"	"emerging"	"27748748"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"NTRK1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"crizotinib"	"case report"	"emerging"	"ASCO 2013 (abstr 8023)"	"sensitivity"	"TRK inhibitors"	"preclinical"	"emerging"	"24162815"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"inflammatory_myofibroblastic_tumor"	"ROS1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"crizotinib"	"case report"	"emerging"	"24875859"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ROS1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"crizotinib"	"FDA-approved"	"consensus"	"FDA"	"response"	"cabozantinib"	"case report"	"emerging"	"27370605"	"sensitivity"	"HSP90 inhibitors"	"preclinical"	"emerging"	"23533265"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"renal"	"MET"	"exon 16-19 p.1132-1330"	"mutation"	"gain-of-function"	"response"	"crizotinib"	"early trials"	"emerging"	"AACR 2016 (abstr CT2006)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MET"	"exon 14 skipping"	"splice site mutation"	"gain-of-function"	"response"	"crizotinib"	"early trials"	"emerging"	"ASCO 2016 (abstr 108), ASCO 2017 (abstr 8511)"	"response"	"crizotinib, cabozantinib"	"case report"	"emerging"	"25971938, 26215952"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"ALK"	"F856S, A348D"	"missense mutation"	"gain-of-function"	"sensitivity"	"crizotinib"	"preclinical"	"emerging"	"26032424"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"ALK"	"R1275Q, G1128A, I1171N, R1192P, F1245C"	"missense mutation"	"gain-of-function"	"sensitivity"	"crizotinib"	"preclinical"	"emerging"	"22072639"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MET"	"V1110I, H1112R, M1250I, R988C, T1010I"	"missense mutation"	"gain-of-function"	"sensitivity"	"crizotinib"	"preclinical"	"emerging"	"17483355"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"MET"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"crizotinib + trastuzumab (in HER2 co-amplified)"	"case report"	"emerging"	"26432108"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ALK"	"I1171T"	"missense mutation"	"gain-of-function"	"resistance"	"crizotinib, alectinib"	"case report"	"emerging"	"25228534"	"response"	"ceritinib"	"FDA-approved"	"consensus"	"25228534"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ROS1"	"S1986Y, S1986F"	"missense mutation"	"gain-of-function"	"resistance"	"crizotinib, ceritinib"	"case report"	"emerging"	"27401242"	"response"	"lorlatinib"	"case report"	"emerging"	"27401242"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ALK"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"crizotinib, ceritinib, alectinib"	"FDA-approved"	"consensus"	"FDA"	"response"	"novel ALK inhibitors"	"early trials"	"emerging"	"23639470"	"response"	"HSP90 inhibitors"	"early trials"	"emerging"	"23553849"	"sensitivity"	"ALK inhibitors + IGF1R inhibitors"	"preclinical"	"emerging"	"25173427"	"sensitivity"	"ALK inhibitors + SRC inhibitors"	"preclinical"	"emerging"	"25394791"	"sensitivity"	"ALK inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"26301689"	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"BRAF"	"V600E"	"missense mutation"	"gain-of-function"	"response"	"dabrafenib"	"case report"	"emerging"	"23470635, 22608338"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"neuroendocrine"	"BRAF"	"V600E"	"missense mutation"	"gain-of-function"	"response"	"dabrafenib + trametinib"	"case report"	"emerging"	"27048246"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"BRAF"	"Y472C"	"missense mutation"	"reduced kinase activity"	"response"	"dasatinib"	"case report"	"emerging"	"22649091"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"KIT"	"D816V"	"missense mutation"	"gain-of-function"	"response"	"dasatinib"	"case report"	"emerging"	"18986703"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"systemic_mastocytosis"	"KIT"	"D816V"	"missense mutation"	"gain-of-function"	"response"	"dasatinib"	"early trials"	"emerging"	"18559612"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"EPHA2"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"18047674, 19010823, 19861960"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"BRAF"	"G466V"	"missense mutation"	"reduced kinase activity"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"22649091"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"atypical_chronic_myeloid_leukemia"	"CSF3R"	"Q741X, Y752X, W791X, D771fs, S783fs"	"missense mutation"	"gain-of-function"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"23656643"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_squamous"	"DDR2"	"I638F, L239R, G253C, G774V, L63V, G505S"	"missense mutation"	"gain-of-function"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"22328973"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"biliary_tract"	"IDH1"	"R132"	"missense mutation"	"gain-of-function"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"27231123"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"biliary_tract"	"IDH2"	"R172"	"missense mutation"	"gain-of-function"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"27231123"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"KIT"	"N822K"	"missense mutation"	"gain-of-function"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"23149070"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_squamous"	"DDR2"	"S768R"	"missense mutation"	"gain-of-function"	"response"	"dasatinib + erlotinib"	"case report"	"emerging"	"22328973"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"22328973"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphoblastic_leukemia"	"BCR-ABL1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"dasatinib + venetoclax"	"preclinical"	"emerging"	"27582059"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"MLL"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"daunorubicin"	"FDA-approved"	"consensus"	"22417203"	"sensitivity"	"HDAC inhibitors"	"preclinical"	"emerging"	"22015773"	"sensitivity"	"DOT1L inhibitors"	"preclinical"	"emerging"	"21741596"	"sensitivity"	"BET inhibitors"	"preclinical"	"emerging"	"21964340"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"DNMT3A"	"any"	"mutation"	"loss-of-function"	"response"	"daunorubicin"	"FDA-approved"	"consensus"	"22417203"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"NPM1"	"any"	"mutation"	"loss-of-function"	"response"	"daunorubicin"	"FDA-approved"	"consensus"	"22417203"	"response"	"ATRA (non-FLT3 ITD AML)"	"late trials"	"emerging"	"19059939"	"sensitivity"	"DOT1L inhibitors + MLL1 inhibitors"	"preclinical"	"emerging"	"27535106"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"TP53"	"mut"	"mutation"	"loss-of-function"	"response"	"decitabine"	"early trials"	"emerging"	"27959731"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myelodisplastic_syndrome"	"TP53"	"mut"	"mutation"	"loss-of-function"	"response"	"decitabine"	"early trials"	"emerging"	"27959731"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lymphoma"	"ATM"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"DNA-PKc inhibitors"	"preclinical"	"emerging"	"23761041"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MSH3"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"DNA-PKcs inhibitors"	"preclinical"	"emerging"	"24556366"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"FGFR2"	"V565I, M536I, M538I, I548V, N550, E566G, L618M, K660E"	"missense mutation"	"gain-of-function"	"resistance"	"dovitinib"	"preclinical"	"emerging"	"23908597"	"resistance, sensitivity"	"ponatinib"	"preclinical"	"emerging"	"23908597"	"sensitivity, "	"selective FGFR inhibitor, "	"preclinical, "	"emerging, "	"ENA 2014 (abstr 381), "	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"FGF3"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"dovitinib"	"early trials"	"emerging"	"23658459"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"FGF4"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"dovitinib"	"early trials"	"emerging"	"23658459"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"EGFR"	"amplification"	"copy number gain"	"gain-of-function"	"no response"	"EGFR TKIs"	"early trials"	"emerging"	"16282176, 16278407"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"EGFR"	"exon 2-7 p.30-336"	"deletion mutation"	"gain-of-function"	"no response"	"EGFR TKIs"	"early trials"	"emerging"	"19204207"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"BRAF"	"V600E, G469A"	"missense mutation"	"gain-of-function"	"resistance"	"EGFR TKIs"	"case report"	"emerging"	"22773810"	"response, sensitivity"	"dabrafenib + trametinib, EGFR TKIs + MEK inhibitors in EGFR mutant"	"FDA-approved, preclinical"	"consensus, emerging"	"27283860, 22773810"	"response, "	"dabrafenib, "	"early trials, "	"emerging, "	"27080216, "	"response, "	"vemurafenib, "	"case report, "	"emerging, "	"22743296, "	"response, "	"ERK inhibitors, "	"early trials, "	"emerging, "	"ASCO 2017 (abstr 2508), "	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"KRAS"	"any"	"mutation"	"gain-of-function"	"resistance"	"EGFR TKIs"	"NCCN guidelines"	"consensus"	"20921461"	"response"	"MEK inhibitors"	"early trials"	"emerging"	"23200175, 24947927, 25667274, 25722381"	"no response"	"selumetinib"	"early trials"	"emerging"	"26802155"	"response"	"PI3K pathway inhibitors + MEK inhibitors"	"early trials"	"emerging"	"25516890"	"response"	"fatty acid synthase inhibitors"	"case report"	"emerging"	"AACR 2016 (abstr LB214)"	"response"	"pan-RAF inhibitors"	"case report"	"emerging"	"AACR 2016 (abstr CT005)"	"response"	"CDK4/CDK6 inhibitor abemaciclib"	"early trials"	"emerging"	"27217383"	"response"	"pan-RAF inhibitor"	"early trials"	"emerging"	"AACR 2017 (abstr  CT002)"
"colorectal"	"ALK"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"entrictinib, ceritinib"	"case report"	"emerging"	"26633560, 26933125"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"AR"	"F877L/T878A coexisting"	"missense mutation"	"gain-of-function"	"sensitivity"	"enzalutamide"	"preclinical"	"emerging"	"27196756"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"AR-V7"	"splice variant mRNA"	"amplification"	"gain-of-function"	"resistance"	"enzalutamide, abiraterone"	"early trials"	"emerging"	"25184630"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"AR"	"F876L "	"missense mutation"	"gain-of-function"	"resistance"	"enzalutamide, ARN-509"	"case report"	"emerging"	"23779130"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"BCOR"	"mut"	"mutation"	"loss-of-function"	"sensitivity"	"enzastaurin (PKCbeta inhibitor)"	"preclinical"	"emerging"	"27397505"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"EPHA3"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"EPHA3 inhibitors"	"preclinical"	"emerging"	"25125683"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"ERBB2"	"E321G, C334S"	"missense mutation"	"gain-of-function"	"sensitivity"	"ERBB2 TKIs"	"preclinical"	"emerging"	"22908275"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"ERBB2"	"G309E, S310F, S310Y, C311R "	"missense mutation"	"gain-of-function"	"sensitivity"	"ERBB2 TKIs, trastuzumab"	"preclinical"	"emerging"	"22908275"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"biliary_tract"	"BRAF"	"L485W"	"missense mutation"	"gain-of-function"	"response"	"ERK inhibitors"	"case report"	"emerging"	"ASCO 2017 (abstr 2508)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"BRAF"	"G469A"	"missense mutation"	"gain-of-function"	"response"	"ERK inhibitors"	"case report"	"emerging"	"ASCO 2017 (abstr 2508)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"NRAS"	"G12C"	"missense mutation"	"gain-of-function"	"sensitivity"	"ERK inhibitors"	"preclinical"	"emerging"	"23614898"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"amplification"	"copy number gain"	"gain-of-function"	"no response"	"erlotinib"	"early trials"	"emerging"	"ASCO 2015 (abstr e19028)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"S720"	"missense mutation"	"gain-of-function"	"no response"	"erlotinib"	"case report"	"emerging"	"26773740"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"IGF1R"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"erlotinib"	"preclinical"	"emerging"	"24458568"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR-RAD51"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"erlotinib"	"case report"	"emerging"	"27102076"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"V769_770insASV"	"insertion mutation"	"gain-of-function"	"response"	"erlotinib"	"case report"	"emerging"	"26773740, 23328547"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"K757R, E746G"	"missense mutation"	"gain-of-function"	"response"	"erlotinib"	"case report"	"emerging"	"26773740"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"EGFR"	"A289V, R108K, G598V, T263P"	"missense mutation"	"gain-of-function"	"sensitivity"	"erlotinib"	"preclinical"	"emerging"	"17177598"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"T790M"	"missense mutation"	"gain-of-function"	"resistance"	"erlotinib, afatinib"	"NCCN guidelines"	"consensus"	"NCCN"	"response"	"osimertinib"	"FDA"	"consensus"	"FDA"	"response"	"afatinib + cetuximab"	"early trials"	"emerging"	"25074459"	"response"	"afatinib + nimotuzumab"	"early trials"	"emerging"	"26667485"	"response"	"HSP90 inhibitors"	"early trials"	"emerging"	"ESMO 2012 (abstr 4380)"	"response"	"irreversible EGFR T790M inhibitors"	"early trials"	"emerging"	"ASCO 2014 (abstr 8009), ENA 2014 (abstr 10LBA), ENA 2014 (abstr 9LBA), ASCO 2015 (abstr 8001)"	"sensitivity"	"MEK inhibitors (alone or in combination)"	"preclinical"	"emerging"	"23102728"	""	""	""	""	""
"lung"	"EGFR"	"exon 19 p.729-761"	"insertion mutation"	"gain-of-function"	"response"	"erlotinib, afatinib"	"NCCN guidelines"	"consensus"	"22190593"	"response"	"irreversible EGFR TKIs"	"late trials"	"emerging"	"22753918"	"response"	"afatinib + cetuximab"	"early trials"	"emerging"	"ESMO 2012 (abstr 1289)"	"response"	"HSP90 inhibitors"	"early trials"	"emerging"	"ESMO 2012 (abstr 4380)"	"sensitivity"	"MEK inhibitors (alone or in combination)"	"preclinical"	"emerging"	"23102728"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"L861Q, G719A, G719S, G719C, G719D, L747S, S768I, L861P, L861R"	"missense mutation"	"gain-of-function"	"response"	"erlotinib, afatinib"	"NCCN guidelines"	"consensus"	"NCCN"	"response"	"irreversible EGFR TKIs"	"late trials"	"emerging"	"22753918"	"response"	"afatinib + cetuximab"	"early trials"	"emerging"	"ESMO 2012 (abstr 1289)"	"response"	"HSP90 inhibitors"	"early trials"	"emerging"	"ESMO 2012 (abstr 4380)"	"sensitivity"	"MEK inhibitors (alone or in combination)"	"preclinical"	"emerging"	"23102728"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"exon 19 p.729-761"	"deletion mutation"	"gain-of-function"	"response"	"erlotinib, afatinib, gefitinib"	"FDA-approved"	"consensus"	"FDA"	"response"	"afatinib"	"late trials"	"emerging"	"22753918, 25589191"	"response"	"afatinib + cetuximab"	"early trials"	"emerging"	"ESMO 2012 (abstr 1289)"	"response"	"HSP90 inhibitors"	"early trials"	"emerging"	"ESMO 2012 (abstr 4380)"	"sensitivity"	"MEK inhibitors (alone or in combination)"	"preclinical"	"emerging"	"23102728"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"L858R"	"missense mutation"	"gain-of-function"	"response"	"erlotinib, afatinib, gefitinib"	"FDA-approved"	"consensus"	"FDA"	"response"	"irreversible EGFR TKIs"	"late trials"	"emerging"	"22753918"	"response"	"afatinib + cetuximab"	"early trials"	"emerging"	"ESMO 2012 (abstr 1289)"	"response"	"HSP90 inhibitors"	"early trials"	"emerging"	"ESMO 2012 (abstr 4380)"	"sensitivity"	"MEK inhibitors (alone or in combination)"	"preclinical"	"emerging"	"23102728"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MTOR"	"F2108L"	"missense mutation"	"gain-of-function"	"resistance"	"everolimus"	"case report"	"emerging"	"25295501"	"sensitivity"	"mTOR kinase inhibitors"	"preclinical"	"emerging"	"25295501"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"fibrous_histiocytoma"	"AKT1"	"H238Y"	"missense mutation"	"gain-of-function"	"response"	"everolimus"	"case report"	"emerging"	"ASCO 2015 (abstr 11010)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"angiosarcoma"	"MTOR"	"I1973F, K1771R"	"missense mutation"	"gain-of-function"	"response"	"everolimus"	"case report"	"emerging"	"ASCO 2015 (abstr 11010), 26859683"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"MTOR"	"E2014K, E2419K, N1421D"	"missense mutation"	"gain-of-function"	"response"	"everolimus"	"case report"	"emerging"	"24625776, ASCO 2015 (abstr 11010)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"MTOR"	"K1771R, N1421D"	"missense mutation"	"gain-of-function"	"response"	"everolimus"	"case report"	"emerging"	"ASCO 2015 (abstr 11010), 26859683"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"renal"	"MTOR"	"I1973F, Q2223K"	"missense mutation"	"gain-of-function"	"response"	"everolimus"	"case report"	"emerging"	"26859683, 24622468"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"NF1"	"D1644A"	"missense mutation"	"loss-of-function"	"response"	"everolimus"	"case report"	"emerging"	"26859683"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"pancreatic"	"STK11"	"D194E"	"missense mutation"	"loss-of-function"	"response"	"everolimus"	"case report"	"emerging"	"21189378"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"TSC1"	"any"	"mutation"	"loss-of-function"	"response"	"everolimus"	"early trials"	"emerging"	"22923433"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"sarcoma"	"TSC1"	"any"	"mutation"	"loss-of-function"	"response"	"everolimus"	"case report"	"emerging"	"26859683"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"TSC2"	"any"	"mutation"	"loss-of-function"	"response"	"everolimus"	"case report"	"emerging"	"26859683"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thyroid"	"TSC2"	"any"	"mutation  "	"loss-of-function"	"response"	"everolimus"	"case report"	"emerging"	"25295501"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"renal"	"FLCN"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"everolimus"	"case report"	"emerging"	"23995526"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thyroid"	"FLCN"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"everolimus"	"case report"	"emerging"	"25295501"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"schwannoma"	"NF2"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"everolimus"	"early trials"	"emerging"	"25567352"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"everolimus"	"early trials"	"emerging"	"23582881"	"sensitivity"	"PI3K pathway inhibitors + AR antagonists"	"preclinical"	"emerging"	"21575859"	"response"	"PI3K beta inhibitor"	"case report"	"emerging"	"ASCO 2014 (abstr 2514)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"renal"	"TSC1"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"everolimus"	"case report"	"emerging"	"24622468, 26859683, ASCO 2015 (abstr 11010), ASCO 2015 (abstr 4519)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"malignant_peripheral_nerve_sheat_tumor, leukemia"	"NF1"	"any"	"mutation or copy number loss"	"loss-of-function"	"no response"	"everolimus + bevacizumab"	"early trials"	"emerging"	"ASCO 2016 (abstr 11053)"	"sensitivity"	"mTOR inhibitors"	"preclinical"	"emerging"	"18483311, 20505189, 24509877"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"23221341"	"sensitivity"	"mTOR inhibitors + HSP90 inhibitors"	"preclinical"	"emerging"	"21907929"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"CTNNB1"	"H36Y, S37C, S37Y, D32V"	"missense mutation"	"gain-of-function"	"response"	"everolimus + letrozole"	"early trials"	"emerging"	"25624430"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"hepatocellular_carcinoma"	"NF1"	"mut"	"mutation"	"loss-of-function"	"response"	"everolimus + pazopanib"	"case report"	"emerging"	"24931142"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ESR1"	"any"	"missense mutation"	"gain-of-function"	"resistance"	"exemestane"	"late trials"	"emerging"	"27269946"	"response"	"fulvestrant"	"late trials"	"emerging"	"27269946"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"malignant_rhabdoid_tumor"	"INI1"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"EZH2 inhibitor"	"case report"	"emerging"	"ENA 2014 (abstr 6LBA), ESMO 2015 (abstract 302)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian_rhabdoid_tumor"	"SMARCA4"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"EZH2 inhibitor"	"case report"	"emerging"	"ESMO 2015 (abstract 302)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lymphoma"	"EZH2"	"Y641F, A677"	"missense mutation"	"gain-of-function"	"sensitivity"	"EZH2 inhibitor"	"preclinical"	"emerging"	"24563539, 23023262"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"ARID1A"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"EZH2 inhibitor"	"preclinical"	"emerging"	"25686104"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"mesothelioma"	"BAP1"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"EZH2 inhibitor"	"preclinical"	"emerging"	"26437366"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"PBRM1"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"EZH2 inhibitor in RAS wt"	"preclinical"	"emerging"	"26552009"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"SMARCA1"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"EZH2 inhibitor in RAS wt"	"preclinical"	"emerging"	"26552009"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"neuroblastoma"	"MYC"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"FACT inhibitor"	"preclinical"	"emerging"	"26537256"	"sensitivity"	"BET inhibitors"	"preclinical"	"emerging"	"23430699"	"sensitivity"	"CDK7 inhibitors"	"preclinical"	"emerging"	"25416950"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"mesothelioma"	"NF2"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"FAK inhibitors"	"early trials"	"emerging"	"ENA 2012 (abstr 610)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"biliary_tract"	"FGFR2"	"multiple, mut"	"missense mutation"	"gain-of-function"	"resistance"	"FGFR inhibitors"	"early trials"	"emerging"	"28034880, ASCO 2017 (abstr 2500)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloma"	"FGFR3"	"V555M"	"missense mutation"	"gain-of-function"	"resistance"	"FGFR inhibitors"	"preclinical"	"emerging"	"22869148"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"FGFR1"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"FGFR inhibitors"	"early trials"	"emerging"	"25193991"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_squamous"	"FGFR1"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"FGFR inhibitors"	"case report"	"emerging"	"27870574"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"FGFR2"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"FGFR inhibitors"	"case report"	"emerging"	"25193991"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"FGFR2"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"FGFR inhibitors"	"early trials"	"emerging"	"ASCO 2015 (abstr 2508)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"biliary_tract"	"FGFR2"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"FGFR inhibitors"	"early trials"	"emerging"	"ASCO 2016 (abstr 109)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"FGFR2"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"FGFR inhibitors"	"early trials"	"emerging"	"ASCO 2017 (abstr 2500)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"FGFR3"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"FGFR inhibitors"	"case report"	"emerging"	"26324363, ASCO 2017 (abstr 2500)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"FGFR3"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"FGFR inhibitors"	"early trials"	"emerging"	"26324363"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"FGFR3"	"any"	"mutation"	"gain-of-function"	"response"	"FGFR inhibitors"	"early trials"	"emerging"	"27870574"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"FGFR1"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"case report"	"emerging"	"ASCO 2017 (abstr 2500)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"FGFR1"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"23418312"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"liposarcomas"	"FRS2"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"23393200"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"biliary_tract"	"FGFR2"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"23558953"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"FGFR2"	"A266_S267ins"	"insertion mutation"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"26048680"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"FGFR2"	"S252W, N549K"	"missense mutation"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"18552176, 22238366, 23002168"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_squamous"	"FGFR2"	"W290C, S320C, K660N"	"missense mutation"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"23786770, 25035393"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"FGFR3"	"S249C, G691R"	"missense mutation"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"27998968"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"rhabdomyosarcoma"	"FGFR4"	"N535, V550"	"missense mutation"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"19809159, 24124571"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"FGFR2"	"290_291WI>C"	"mutation"	"gain-of-function"	"sensitivity"	"FGFR inhibitors"	"preclinical"	"emerging"	"26048680"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"exon 20 p.762-823"	"insertion mutation"	"gain-of-function"	"decreased sensitivity"	"first-generation and irreversible EGFR TKIs"	"late trials"	"emerging"	"21764376, 26773740,  26051236"	"response"	"HSP90 inhibitors"	"early trials"	"emerging"	"ASCO 2014 (abstr 8015)"	"sensitivity"	"osimertinib"	"preclinical"	"emerging"	"26515464"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"U2AF1"	"mut"	"mutation"	"loss-of-function"	"sensitivity"	"FLT3 inhibitors"	"preclinical"	"emerging"	"27397505"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"AR"	"T877A"	"missense mutation"	"gain-of-function"	"resistance"	"flutamide"	"case report"	"emerging"	"2260966"	"sensitivity"	"enzalutamide, ARN-509"	"preclinical"	"emerging"	"23779130"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ESR1"	"Y537S"	"missense mutation"	"gain-of-function"	"reduced sensitivity"	"fulvestrant"	"preclinical"	"emerging"	"27986707"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"pancreatic"	"RNF43"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"FZD5 antibodies"	"preclinical"	"emerging"	"27869803"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"NOTCH1"	"PEST domain p.2245-2536, HD p.1529-1723"	"mutation"	"gain-of-function"	"response"	"Gamma secretase inhibitors"	"early trials"	"emerging"	"ASCO 2006 (abstr 6585)"	"sensitivity"	"Gamma secretase inhibitors"	"preclinical"	"emerging"	"15472075, 19778842, 22510873, 23001755, 15472075, 19778842, 22510873, 23001755 "	"sensitivity"	"Gamma secretase inhibitors + mTOR inhibitors"	"preclinical"	"emerging"	"19246562"	"sensitivity"	"Gamma secretase inhibitors + CDK4 inhibitors"	"preclinical"	"emerging"	"19318552"	"response"	"steroids early setting"	"late trials"	"emerging"	"20861909, 20861920, 20944675"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"NOTCH1"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"Gamma secretase inhibitors"	"preclinical"	"emerging"	"16688224, 23033986"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"NOTCH1"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"Gamma secretase inhibitors"	"preclinical"	"emerging"	"22101766"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"NOTCH2"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"Gamma secretase inhibitors"	"preclinical"	"emerging"	"22101766"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"NOTCH1"	"PEST domain p.2245-2536"	"mutation"	"gain-of-function"	"sensitivity"	"Gamma secretase inhibitors"	"preclinical"	"emerging"	"25564152"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"mantle_cell_lymphoma"	"NOTCH1"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"Gamma secretase inhibitors"	"preclinical"	"emerging"	"22210878"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"NOTCH2"	"PEST domain p.2010-2472"	"mutation"	"gain-of-function"	"sensitivity"	"Gamma secretase inhibitors"	"preclinical"	"emerging"	"25564152"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"EGFR"	"amplification"	"copy number gain"	"gain-of-function"	"no response"	"gefitinib"	"early trials"	"emerging"	"21274259, 22261807"	"response"	"EGFR inhibitors"	"case report"	"emerging"	"26763254"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"EGFR"	"delL747-P753insS"	"indel"	"gain-of-function"	"no response"	"gefitinib"	"case report"	"emerging"	"21274259"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"EGFR"	"V843I"	"missense mutation"	"gain-of-function"	"no response"	"gefitinib"	"case report"	"emerging"	"21274259"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"esophageal"	"EGFR"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"gefitinib"	"late trials"	"emerging"	"24950987"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"pancreatic"	"KRAS"	"any"	"mutation"	"gain-of-function"	"response"	"gemcitabine + MEK inhibitors"	"early trials"	"emerging"	"23583440"	"no response"	"PI3K pathway inhibitors + MEK inhibitor"	"early trials"	"emerging"	"ASCO 2015 (abstr 4119)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"malignant_rhabdoid_tumor"	"SMARCB1"	"mut"	"mutation"	"loss-of-function"	"sensitivity"	"HDAC inhibitors"	"preclinical"	"emerging"	"26920892"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BAP1"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"HDAC inhibitors"	"preclinical"	"emerging"	"22038994"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"TP53"	"wild type"	"no mutation"	"loss-of-function"	"response"	"HDM2 inhibitor"	"early trials"	"emerging"	"AACR 2017 (abstr CT152)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"TP53"	"R248Q, R175H"	"missense mutation"	"gain-of-function"	"sensitivity"	"HSP90 inhibitors"	"preclinical"	"emerging"	"26009011"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"chronic_lymphocytic_leukemia"	"BTK"	"C481S"	"missense mutation"	"gain-of-function"	"resistance"	"ibrutinib"	"early trials"	"emerging"	"24869598, 27199251"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"mantle_cell_lymphoma"	"BTK"	"C481"	"missense mutation"	"gain-of-function"	"resistance"	"ibrutinib"	"case report"	"emerging"	"25082755"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"chronic_lymphocytic_leukemia"	"PLCG2"	"R665W, L845F"	"missense mutation"	"gain-of-function"	"resistance"	"ibrutinib"	"early trials"	"emerging"	"24869598"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lymphoma"	"MYD88"	"L265P"	"missense mutation"	"gain-of-function"	"response"	"ibrutinib"	"case report"	"emerging"	"26244327"	"sensitivity"	"JAK inhibitors"	"preclinical"	"emerging"	"21179087"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"waldenstrom macroglobulinemia"	"MYD88"	"L265P"	"missense mutation"	"gain-of-function"	"response"	"ibrutinib"	"FDA-approved"	"emerging"	"25853747"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"IDH1"	"unknown"	"missense mutation"	"switch-of-function"	"response"	"IDH1 inhibitor"	"early trials"	"emerging"	"ENA 2014 (abstr 1LBA)"	"sensitivity"	"BCL2 inhibitors"	"preclinical"	"emerging"	"25599133"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"IDH1"	"R132H"	"missense mutation"	"switch-of-function"	"sensitivity"	"IDH1 inhibitor"	"preclinical"	"emerging"	"23558169"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"IDH2"	"R140Q, R172K"	"missense mutation"	"switch-of-function"	"response"	"IDH2 inhibitor"	"early trials"	"emerging"	"AACR 2014 (abstr CT103)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"sarcoma"	"PTPRD"	"mut"	"missense mutation"	"gain-of-function"	"response"	"IGF-1R antibodies"	"case report"	"emerging"	"23800680"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"KIT"	"wild type"	"no mutation"	"not applicable"	"decreased sensitivity"	"imatinib"	"late trials"	"emerging"	"18955458"	"response"	"sunitinib"	"late trials"	"emerging"	"18955458"	"response"	"sorafenib"	"early trials"	"emerging"	"ASCO 2011 (abstr 10009)"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"16397263"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"PDGFRA"	"wild type"	"no mutation"	"not applicable"	"decreased sensitivity"	"imatinib"	"late trials"	"emerging"	"14645423, 18955458"	"response"	"sunitinib"	"late trials"	"emerging"	"18955458"	"response"	"sorafenib"	"early trials"	"emerging"	"ASCO 2011 (abstr 10009)"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"16397263"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"KIT"	"amplification"	"copy number gain"	"gain-of-function"	"no response"	"imatinib"	"early trials"	"emerging"	"23775962"	"no response"	"sunitinib"	"early trials"	"emerging"	"22261812"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"KIT"	"V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D, T670I"	"missense mutation"	"gain-of-function"	"resistance"	"imatinib"	"preclinical, case report"	"emerging"	"23582185, 21689725, 17259998, 24687822"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"KIT"	"exon 17 p.788-828, exon 18 p.829-860"	"missense mutation"	"gain-of-function"	"resistance"	"imatinib"	"early trials"	"emerging"	"21690468, 21642685"	"response"	"sorafenib"	"case report"	"emerging"	"20372153"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"KRAS"	"G12"	"missense mutation"	"gain-of-function"	"resistance"	"imatinib"	"case report"	"emerging"	"24687822"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"hypereosinophilic_syndrome"	"PDGFRA"	"T674I"	"missense mutation"	"gain-of-function"	"resistance"	"imatinib"	"case report"	"emerging"	"12660384"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thymic"	"KIT"	"V560del"	"deletion mutation"	"gain-of-function"	"response"	"imatinib"	"case report"	"emerging"	"15201427"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"dermatofibrosarcoma"	"COL1A1-PDGFRB"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"imatinib"	"FDA-approved"	"consensus"	"FDA"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"hypereosinophilic_syndrome"	"PDGFRA"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"imatinib"	"FDA-approved"	"consensus"	"FDA"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloproliferative_neoplasm"	"PDGFRA"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"imatinib"	"FDA-approved"	"consensus"	"FDA"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"KIT"	"exon 11 p.550-592, exon 13 p.627-664 , D820Y"	"missense mutation"	"gain-of-function"	"response"	"imatinib"	"NCCN guidelines, case report"	"consensus, emerging"	"NCCN, 23775962"	"response"	"imatinib, sunitinib, nilotinib"	"late trials, case report"	"emerging"	"18421059, 21642685, 21690468, 22261812 , 25695690"	"response, "	"dasatinib, "	"case report, "	"emerging, "	"19671763, "	"response, "	"sorafenib, "	"case report, "	"emerging, "	"18936790, "	"response, "	"nilotinib, "	"early trials, "	"emerging, "	"22068222, 25695690, "	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thymic"	"KIT"	"Y553N"	"missense mutation"	"gain-of-function"	"response"	"imatinib"	"case report"	"emerging"	"21969494"	"response"	"sunitinib"	"case report"	"emerging"	"23375402"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"KIT"	"exon 8 p.416-422"	"indel"	"gain-of-function"	"sensitivity"	"imatinib"	"preclinical"	"emerging"	"15618474"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloproliferative_neoplasm"	"CSF1R"	"Y571D"	"missense mutation"	"gain-of-function"	"sensitivity"	"imatinib"	"preclinical"	"emerging"	"18971950"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"PDGFRA"	"P577S, R841K, H845Y, G853D"	"missense mutation"	"gain-of-function"	"sensitivity"	"imatinib, crenolanib"	"preclinical"	"emerging"	"24132921"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"chronic_myeloid_leukemia"	"BCR-ABL1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"imatinib, dasatinib, nilotinib, bosutinib, ponatinib"	"FDA-approved"	"consensus"	"FDA"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"BCR-ABL1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"imatinib, dasatinib, ponatinib"	"FDA-approved"	"consensus"	"FDA"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"PDGFRA"	"D842V"	"missense mutation"	"gain-of-function"	"resistance"	"imatinib, sunitinib"	"late trials, preclinical"	"emerging"	"22718859, 16638875"	"response"	"crenolanib"	"early trials"	"emerging"	"ASCO 2016 (abstr 11010)"	"sensitivity"	"HSP90 inhibitors"	"preclinical"	"emerging"	"18794084"	"sensitivity"	"dasatinib"	"preclinical"	"emerging"	"18794084"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"PDGFRA"	"R748G,Y894C"	"missense mutation"	"gain-of-function"	"response"	"imatinib, sunitinib, regorafenib"	"NCCN guidelines"	"consensus"	"NCCN"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"KIT"	"exon 9 p.449-514, exon 11 p.550-592, exon 14 p.664-714, exon 17 p.788-828, exon 13 p.627-664"	"mutation"	"gain-of-function"	"response"	"imatinib, sunitinib, regorafenib"	"FDA-approved"	"consensus"	"FDA"	"decreased sensitivity"	"imatinib (low dose), sunitinib, imatinib, imatinib, sunitinib"	"late trials, preclinical"	"emerging"	"18955458, 18955451, 16624552, 18955458, 23840364"	"response, "	"sorafenib, , nilotinib"	"early trials, "	"emerging, "	"22270258, , 22119758, 21456006"	"sensitivity, response, "	"HSP90 inhibitors, , sorafenib"	"preclinical, early trials, "	"emerging, "	"21737509, 22898035, , 23840364"	", response, sensitivity"	", ponatinib, HSP90 inhibitors"	", early trials, preclinical"	", emerging"	", 25239608, ASCO 2015 (abstr 10535), 21737509"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"PDGFRA"	"exon 12 p.552-596, exon 14 p.631-668, exon 18 p.814-854"	"mutation"	"gain-of-function"	"response"	"imatinib, sunitinib, regorafenib"	"NCCN guidelines"	"consensus"	"NCCN"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"RAD50"	"L1237F"	"missense mutation"	"loss-of-function"	"response"	"irinotecan plus CHK1/2 inhibitor in ATM deficient tumor"	"case report"	"emerging"	"24934408"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"JAK2"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"JAK inhibitors"	"preclinical"	"emerging"	"27075627"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"GNAS"	"R201"	"missense mutation"	"gain-of-function"	"sensitivity"	"JAK inhibitors"	"preclinical"	"emerging"	"21835143"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lymphoma"	"JAK3"	"A572V, A573V"	"missense mutation"	"gain-of-function"	"sensitivity"	"JAK inhibitors"	"preclinical"	"emerging"	"22705984"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"megakaryoblastic_leukemia"	"JAK3"	"R657Q, I87T, Q501H"	"missense mutation"	"gain-of-function"	"sensitivity"	"JAK inhibitors"	"preclinical"	"emerging"	"18397343"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloproliferative_neoplasm"	"MPL"	"W515F"	"missense mutation"	"gain-of-function"	"sensitivity"	"JAK inhibitors"	"preclinical"	"emerging"	"16834459"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lymphoma"	"SOCS1"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"JAK inhibitors"	"preclinical"	"emerging"	"22025331"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloproliferative_neoplasm"	"SH2B3"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"JAK inhibitors"	"preclinical"	"emerging"	"20404132"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloproliferative_neoplasm"	"CBL"	"Y371H, C384R"	"missense mutation"	"gain-of-function"	"sensitivity"	"JAK inhibitors, dasatinib"	"preclinical"	"emerging"	"23696637"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB4"	"H809G"	"missense mutation"	"gain-of-function"	"resistance"	"lapatinib"	"case report"	"emerging"	"26530965"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"EGFR"	"E690K"	"missense mutation"	"gain-of-function"	"response"	"lapatinib"	"case report"	"emerging"	"22885469"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB2"	"V659E"	"missense mutation"	"gain-of-function"	"response"	"lapatinib"	"case report"	"emerging"	"23950206"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ERBB2"	"V659E"	"missense mutation"	"gain-of-function"	"response"	"lapatinib"	"case report"	"emerging"	"23950206"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"schwannoma"	"NF2"	"any"	"mutation"	"loss-of-function"	"response"	"lapatinib"	"early trials"	"emerging"	"22844108"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"ERBB4"	"E317K, E452K, E542K, R544W, R393W, E872K"	"missense mutation"	"gain-of-function"	"sensitivity"	"lapatinib"	"preclinical"	"emerging"	"19718025"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ERBB4"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"lapatinib, afatinib"	"preclinical"	"emerging"	"24727320"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB2"	"G309A, V777L, V842I"	"missense mutation"	"gain-of-function"	"sensitivity"	"lapatinib, neratinib"	"preclinical"	"emerging"	"23220880"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"TRKA"	"G595R"	"missense mutation"	"gain-of-function"	"resistance"	"larotrectinib"	"preclinical"	"emerging"	"28578312"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"TRKC"	"G623R"	"missense mutation"	"gain-of-function"	"resistance"	"larotrectinib"	"preclinical"	"emerging"	"28578312"	"response"	"novel TRK inhibitors"	"case report"	"emerging"	"28578312"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"LRP1B"	"any"	"mutation or copy number loss"	"loss-of-function"	"resistance"	"liposomal doxorubicin"	"early trials"	"emerging"	"22896685"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ALK"	"L1198F"	"missense mutation"	"gain-of-function"	"resistance"	"lorlatinib"	"case report"	"emerging"	"26698910"	"response"	"crizotinib"	"case report"	"emerging"	"26698910"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"liposarcomas"	"MDM2"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"MDM2 inhibitors (tumors TP53 wt)"	"early trials"	"emerging"	"23084521, ASCO 2015 (abstr 10564)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"sarcoma"	"MDM4"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"MDM2/MDMX inhibitors"	"preclinical"	"emerging"	"24336067"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"retinoblastoma"	"RB1"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"MDM2/MDMX inhibitors"	"preclinical"	"emerging"	"17080083, 21515735"	"sensitivity"	"HDAC inhibitors"	"preclinical"	"emerging"	"18483379"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MAP2K1"	"I99T, L115, G128D, F129L, V211D, L215P, I103N, K104N, I111N, H119P, E120D, F133L, P124, D67N"	"missense mutation"	"gain-of-function"	"resistance"	"MEK inhibitors"	"preclinical"	"emerging"	"19915144"	", sensitivity"	", ERK inhibitors"	", preclinical"	", emerging"	", 23614898"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"MAP2K1"	"K57N"	"missense mutation"	"gain-of-function"	"resistance"	"MEK inhibitors"	"case report"	"emerging"	"23444215"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"MAP2K1"	"Q56_V60del"	"deletion mutation"	"gain-of-function"	"response"	"MEK inhibitors"	"case report"	"emerging"	"26324360"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"BRAF"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"MEK inhibitors"	"case report"	"emerging"	"26324360"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BRAF"	"K601R"	"missense mutation"	"gain-of-function"	"response"	"MEK inhibitors"	"case report"	"emerging"	"23248257"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"NRAS"	"any"	"missense mutation"	"gain-of-function"	"response"	"MEK inhibitors"	"late trials"	"emerging"	"23414587, ASCO 2016 (abstr 9500)"	"response"	"MEK inhibitors"	"early trials"	"emerging"	"18390968, 22761467"	"response"	"MEK inhibitors + CDK4/6 inhibitors"	"early trials"	"emerging"	"ASCO 2014 (abstr 9009)"	"response"	"pan-RAF inhibitors"	"case report"	"emerging"	"ESMO 2015 (abstract 300), AACR 2017 (abstr CT002)"	"sensitivity"	"HSP90 inhibitors"	"preclinical"	"emerging"	"23538902"	"resistance"	"BRAF inhibitors "	"early trials"	"emerging"	"23569304, 24265153"	"response"	"ERK inhibitors"	"case report"	"emerging"	"ASCO 2017 (abstr 2508)"	""	""	""	""	""
"biliary_tract"	"KRAS"	"any"	"mutation"	"gain-of-function"	"response"	"MEK inhibitors"	"early trials"	"emerging"	"23391555"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BRAF"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"24345920"	"sensitivity"	"sorafenib"	"preclinical"	"emerging"	"238900088"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"KRAS"	"G12"	"missense mutation"	"gain-of-function"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"18701506"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"KRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"22507781"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cervical"	"KRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"22169769"	"sensitivity"	"CDK4/6 inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"27167191"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"NRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"18701506"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"NRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"22507781"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"NRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"23515407"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"STK11"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"19165201"	"resistance"	"MEK inhibitors + docetaxel in KRAS mutant"	"preclinical"	"emerging"	"22425996"	"sensitivity"	"phenformin"	"preclinical"	"emerging"	"23352126"	"sensitivity"	"mTOR inhibitors"	"preclinical"	"emerging"	"19165201"	"sensitivity"	"SRC inhibitors (in combination with PI3K/MEK inhibitors)"	"preclinical"	"emerging"	"20541700"	"resistance"	"PD1 blockade (if KRAS co-mutation)"	"early trials"	"emerging"	"ASCO 2017 (abstr 9016)"	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"HRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"MEK inhibitors +/- mTOR inhibitors"	"preclinical"	"emerging"	"22399013, 22507781"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"MET"	"D1228V"	"missense mutation"	"gain-of-function"	"resistance"	"MET inhibitor"	"case report"	"emerging"	"27694386"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"renal"	"MET"	"kinase domain"	"mutation"	"gain-of-function"	"response"	"MET inhibitor savolitinib"	"early trials"	"emerging"	"28644771"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"MET"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"MET inhibitors"	"early trials"	"emerging"	"ASCO GI 2015 (abstr 1)"	"sensitivity"	"MET inhibitors"	"preclinical"	"emerging"	"22729845, 23327903"	"resistance"	"lapatinib in HER2-amplified"	"preclinical"	"emerging"	"22238368"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"hepatocellular_carcinoma"	"MET"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"MET inhibitors"	"case report"	"emerging"	"ENA 2015 (abstract A55)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"renal"	"MET"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"MET inhibitors"	"early trials"	"emerging"	"23213094, AACR 2016 (abstr CT2006)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"renal"	"MET"	"M1268T, H1094R"	"missense mutation"	"gain-of-function"	"response"	"MET inhibitors"	"case report, early trials"	"emerging"	"23610116, 23213094"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MET"	"H1112L"	"missense mutation"	"gain-of-function"	"sensitivity"	"MET inhibitors"	"preclinical"	"emerging"	"AACR 2012 (abstr 1786)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"FLT3"	"ITD (Y591-597), tyrosine kinase domain (p.610-p.946)"	"mutation"	"gain-of-function"	"response"	"midostaurin"	"late trials"	"emerging"	"ASH 2015"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"NTRK3"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"midostaurin, IGF1R inhibitors, PI3K pathway inhibitors"	"preclinical"	"emerging"	"21148487, 23131561"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"TP53"	"mut"	"mutation"	"loss-of-function"	"sensitivity"	"mitomycin C, gemcitabine, doxorubicin"	"preclinical"	"emerging"	"27397505"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"PIK3R2"	"A171V, N561D"	"missense mutation"	"loss-of-function"	"sensitivity"	"mTOR inhibitors"	"preclinical"	"emerging"	"21984976, 19962665, 21984976"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"NF1"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"mTOR inhibitors"	"preclinical"	"emerging"	"19573811"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"meningioma, PEComa"	"NF2"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"mTOR inhibitors"	"preclinical"	"emerging"	"19451225, 22426462, 22927055"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"STK11"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"mTOR inhibitors"	"preclinical"	"emerging"	"19541609"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"angiomyolipoma, PEComa"	"TSC1"	"any"	"mutation"	"loss-of-function"	"response"	"mTOR inhibitors "	"early trials"	"emerging"	"23312829, 21525172, 20048174"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"angiomyolipoma, PEComa"	"TSC2"	"any"	"mutation  "	"loss-of-function"	"response"	"mTOR inhibitors "	"early trials"	"emerging"	"23312829, 21525172, 20048174"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_squamous"	"EPHA2"	"G391R"	"missense mutation"	"gain-of-function"	"sensitivity"	"mTOR inhibitors, dasatinib"	"preclinical"	"emerging"	"20360610"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"RICTOR"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"mTORC1/2 inhibitors"	"case report"	"emerging"	"26370156"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"pancreatic"	"PALB2"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"Mytomycin C"	"case report"	"emerging"	"21135251"	"response"	"platinum"	"case report"	"emerging"	"25719666"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"25263539, NCT01585805"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB2"	"T798I"	"missense mutation"	"gain-of-function"	"resistance"	"neratinib"	"case report"	"emerging"	"28274957"	"sensitivity"	"afatinib"	"preclinical"	"emerging"	"28274957"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB2"	"L869R"	"missense mutation"	"gain-of-function"	"response"	"neratinib"	"case report"	"emerging"	"28274957"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"ERBB2"	"S310, L755, V777, P780_Y781insGSP, A775_G776insYVMA"	"mutation"	"gain-of-function"	"response"	"neratinib"	"early trials"	"emerging"	"AACR 2017 (abstr CT001)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB2"	"755-759del"	"deletion mutation"	"gain-of-function"	"sensitivity"	"neratinib"	"preclinical"	"emerging"	"23220880"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB2"	"P780_Y781insGSP"	"insertion mutation"	"gain-of-function"	"sensitivity"	"neratinib"	"preclinical"	"emerging"	"23220880"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB2"	"K753E, L755S"	"missense mutation"	"gain-of-function"	"sensitivity"	"neratinib"	"preclinical"	"emerging"	"27697991, 23220880"	"resistance, "	"lapatinib, "	"preclinical, "	"emerging, "	"27697991, "	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"AR"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"next-generation AR antagonists"	"preclinical"	"emerging"	"23589709, 21859989"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"BCR-ABL1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"nilotinib"	"NCCN guidelines"	"consensus"	"NCCN"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"AKT1"	"E17K"	"missense mutation"	"gain-of-function"	"response"	"non-allosteric AKT inhibitors, allosteric AKT inhibitor"	"early trials"	"emerging"	"ENA 2015 (abstract B109), 28489509"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"adenoid_cystic_carcinoma"	"NOTCH1"	"PEST domain p.2245-2536"	"mutation"	"gain-of-function"	"response"	"NOTCH1 inhibitor"	"case report"	"emerging"	"27870570"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ESR1"	"codons 537, 538"	"missense mutation"	"gain-of-function"	"sensitivity"	"novel estrogen receptor degrader"	"preclinical"	"emerging"	"27020862"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"BRCA1"	"any"	"mutation"	"loss-of-function"	"response"	"olaparib, rucaparib"	"FDA-approved"	"consensus"	"FDA"	"response"	"platinum agents"	"late trials"	"emerging"	"22406760, 22711857"	"response"	"PARP inhibitors + chemotherapy"	"early trials"	"emerging"	"22307137, ASCO 2012 (abstr 1009)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"BRCA2"	"any"	"mutation"	"loss-of-function"	"response"	"olaparib, rucaparib"	"FDA-approved"	"consensus"	"FDA"	"response"	"platinum agents"	"late trials"	"emerging"	"22406760, 22711857"	"response"	"PARP inhibitors + chemotherapy"	"early trials"	"emerging"	"22307137, ASCO 2012 (abstr 1009)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"EGFR"	"C797S, L792, L718"	"missense mutation"	"gain-of-function"	"resistance"	"osimertinib"	"early trials"	"emerging"	"25939061, ASCO 2017 (abstr 2572)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"PAK1"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"PAK inhibitors"	"preclinical"	"emerging"	"23535073"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"schwannoma"	"NF2"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PAK inhibitors"	"preclinical"	"emerging"	"23960073"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"CCND1"	"amplification"	"copy number gain"	"gain-of-function"	"no response"	"palbociclib"	"early trials"	"emerging"	"ASCO 2017 (abstr 9056)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"CDK4"	"amplification"	"copy number gain"	"gain-of-function"	"no response"	"palbociclib"	"early trials"	"emerging"	"ASCO 2017 (abstr 9056)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"BRAF"	"L485-P490"	"deletion mutation"	"gain-of-function"	"response"	"pan-RAF inhibitor"	"preclinical"	"emerging"	"26732095"	"resistance"	"vemurafenib"	"preclinical"	"emerging"	"26732095"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"KRAS"	"any"	"mutation"	"gain-of-function"	"response"	"pan-RAF inhibitors"	"case report"	"emerging"	"AACR 2016 (abstr CT005), AACR 2017 (abstr CT002)"	"resistance"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"22662154"	"sensitivity"	"PI3K pathway inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"21984976, 22662154"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"NTRK1"	"G595R, G667C"	"missense mutation"	"gain-of-function"	"resistance"	"pan-TRK inhibitor"	"preclinical"	"emerging"	"26546295"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"NTRK1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"pan-TRK inhibitor"	"early trials"	"emerging"	"28183697, ASCO 2017 (LBA2501)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"NTRK1"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"pan-TRK inhibitor"	"case report"	"emerging"	"26546295"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"NTRK3"	"rearrangement"	"fusion gene"	"gain-of-function"	"response"	"pan-TRK inhibitor"	"case report"	"emerging"	"AACR 2016 (abstr CT008)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"MAP2K1"	"K57T"	"missense mutation"	"gain-of-function"	"response"	"panitumumab + trametinib"	"case report"	"emerging"	"26644315"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"ATM"	"any"	"mutation"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"26510020"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"BRCA1"	"any"	"mutation"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"20609467, 25366685"	"response"	"platinum agents"	"early trials"	"emerging"	"25847936"	"response"	"veliparib + cisplatin"	"early trials"	"emerging"	"26801247"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"pancreatic"	"BRCA1"	"any"	"mutation"	"loss-of-function"	"response"	"PARP inhibitors"	"case report"	"emerging"	"25366685, 25719666"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"BRCA1"	"any"	"mutation"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"19553641, 25366685, 26510020"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"BRCA2"	"any"	"mutation"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"20609467"	"response"	"platinum agents"	"early trials"	"emerging"	"25847936"	"response"	"veliparib + cisplatin"	"early trials"	"emerging"	"26801247"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"BRCA2"	"any"	"mutation"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"26510020"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"RAD51C"	"any"	"mutation"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"ASCO 2015 (abstr 5508)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"ATM"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"ENA 2014 (abstr 8LBA)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"CHEK2"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"AACR 2015 (abstr CT322), 26510020"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"FANCA"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"26510020"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"HDAC2"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"26510020"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"PALB2"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"PARP inhibitors"	"early trials"	"emerging"	"AACR 2015 (abstr CT322), 26510020"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"PARP inhibitors"	"case report"	"emerging"	"21468130, 20944090"	"no response"	"mTOR inhibitors"	"early trials"	"emerging"	"21788564, 23238879"	"sensitivity"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"22662154"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"ARID1A"	"mut"	"any"	"loss-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"26069190"	"sensitivity"	"EZH2 inhibitors in RAS wt"	"preclinical"	"emerging"	"26552009"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"BRCA1"	"deletion"	"copy number loss"	"loss-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"22392482"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"BRCA2"	"deletion"	"copy number loss"	"loss-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"22392482"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"TMPRSS2"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"21575865"	"sensitivity"	"DNA-PKc inhibitors"	"preclinical"	"emerging"	"21575865"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"IDH1"	"R132"	"missense mutation"	"gain-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"28148839"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"STAG2"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"24356817"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"ATR"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"23548269"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"BAP1"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"22683710"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"renal"	"BAP1"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"22683710"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"CDK12"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"   24240700, 24554720"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"ERCC1"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PARP inhibitors"	"preclinical"	"emerging"	"23934192"	"sensitivity"	"cisplatin"	"preclinical"	"emerging"	"23275151, 23934192"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"FGFR2"	"P253R"	"missense mutation"	"gain-of-function"	"response"	"pazopanib"	"case report"	"emerging"	"23786770"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"B2M"	"any"	"mutation"	"loss-of-function"	"resistance"	"PD1 blockade"	"case report"	"emerging"	"27433843"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"JAK1"	"any"	"mutation"	"loss-of-function"	"resistance"	"PD1 blockade"	"case report"	"emerging"	"27903500"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"JAK1"	"any"	"mutation"	"loss-of-function"	"resistance"	"PD1 blockade"	"case report"	"emerging"	"27433843"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"JAK2"	"any"	"mutation"	"loss-of-function"	"resistance"	"PD1 blockade"	"case report"	"emerging"	"27433843"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"basal_cell_carcinoma"	"CD274"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"PD1 blockade"	"case report"	"emerging"	"27942391"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"POLE"	"exonuclease domain"	"missense mutation"	"gain-of-function"	"response"	"PD1 blockade"	"case report"	"emerging"	"27159395"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"POLE"	"exonuclease domain"	"missense mutation"	"gain-of-function"	"response"	"PD1 blockade"	"case report"	"emerging"	"27001570, 27683556"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BRCA2"	"any"	"mutation"	"loss-of-function"	"response"	"PD1 blockade"	"case report"	"emerging"	"26997480"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"POLE"	"any"	"mutation"	"loss-of-function"	"response"	"PD1 blockade"	"case report"	"emerging"	"28188185"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"NF1"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"PD1 blockade"	"early trials"	"emerging"	"ASCO 2016 (abstr 105)"	"sensitivity"	"trametinib"	"preclinical"	"emerging"	"24576830"	"resistance"	"BRAF inhibitors in BRAF mutant tumor"	"preclinical"	"emerging"	"23288408, 24576830"	"resistance"	"selumetinib in BRAF mutant tumors"	"case report"	"emerging"	"23444215, 23288408"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"CD274"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"PD1 blockade"	"preclinical"	"emerging"	"25079317"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"PDGFRA"	"amplification"	"copy number gain"	"gain-of-function"	"no sensitivity"	"PDGFR inhibitors"	"preclinical"	"emerging"	"23544171"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"response"	"PI3K alpha inhibitors"	"case report"	"emerging"	"ASCO 2015 (abstr 2501)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"resistance"	"PI3K aplha inhibitors"	"early trials, case report"	"emerging"	"25409150"	"response"	"everolimus + trastuzumab + chemotherapy (HER2 ampl)"	"late trials"	"emerging"	"27091708"	"sensitivity"	"ATM inhibitor"	"preclinical"	"emerging"	"27397505"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"response"	"PI3K aplha inhibitors"	"early trials"	"emerging"	"28331003"	"response"	"PI3K pathway inhibitors"	"early trials"	"emerging"	"22271473"	"response"	"everolimus + trastuzumab + chemotherapy (HER2 ampl)"	"late trials"	"emerging"	"27091708"	"response"	"AKT inhibitors"	"early trials"	"emerging"	"ASCO 2015 (abstr 2500)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"no response"	"PI3K pathway inhibitors"	"early trials"	"emerging"	"ASCO 2017 (abstr 9054)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"PIK3CA"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"24366379"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"PIK3CB"	"D1067Y"	"missense mutation"	"gain-of-function"	"resistance"	"PI3K pathway inhibitors"	"case report"	"emerging"	"26759240"	"sensitivity"	"AKT inhibitor, mTORC1/2 inhibitors"	"preclinical"	"emerging"	"26759240"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"AKT1"	"E17K"	"missense mutation"	"gain-of-function"	"response"	"PI3K pathway inhibitors"	"case report"	"emerging"	"26763254"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"bladder"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"response"	"PI3K pathway inhibitors"	"case report"	"emerging"	"ASCO 2015 (abstr 2516)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cervical"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"response"	"PI3K pathway inhibitors"	"early trials"	"emerging"	"22271473, ASCO 2013 (abstr 2531)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"response"	"PI3K pathway inhibitors"	"early trials"	"emerging"	"22271473, 27672108"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"response"	"PI3K pathway inhibitors"	"case report"	"emerging"	"26787751, 26763254"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"response"	"PI3K pathway inhibitors"	"early trials"	"emerging"	"22271473, AACR 2013 (abstr LB-66), 25231405"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"PIK3R1"	"any"	"mutation"	"loss-of-function"	"response"	"PI3K pathway inhibitors"	"case report"	"emerging"	"ASCO 2015 (abstr 11075)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"PDPK1"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"19602588"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"19671762"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thyroid"	"PIK3CA"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"21289267"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"INPP4B"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"23551093"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"23085766, 22932669"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"21673091, 23287563, 21998291"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"21632463"	"sensitivity"	"PI3K pathway inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"21632463"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thyroid"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PI3K pathway inhibitors"	"preclinical"	"emerging"	"21289267"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PI3K pathway inhibitors (alone or in combination)"	"preclinical"	"emerging"	"21325073, 21191045, 17804702"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"PI3K pathway inhibitors (alone or in combination)"	"preclinical"	"emerging"	"23136191"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"KRAS"	"any"	"mutation"	"gain-of-function"	"response"	"PI3K pathway inhibitors + MEK inhibitors"	"early trials"	"emerging"	"25500057, 25516890"	"sensitivity"	"MEK inhibitors"	"preclinical"	"emerging"	"19018267"	"sensitivity"	"decitabine + BCL2 inhibitors"	"preclinical"	"emerging"	"25968887"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cervical"	"HRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"PI3K pathway inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"15950068"	"sensitivity"	"mTOR inhibitors"	"preclinical"	"emerging"	"22345164"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloma"	"KRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"PI3K pathway inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"22985491"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloma"	"NRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"PI3K pathway inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"22985491"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"MYC"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"PIM inhibitors"	"preclinical"	"emerging"	"25505253"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"pancreatic"	"BRCA2"	"any"	"mutation"	"loss-of-function"	"response"	"platinum"	"case report"	"emerging"	"25719666"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"RET"	"I788N"	"missense mutation"	"gain-of-function"	"resistance"	"ponatinib"	"preclinical"	"emerging"	"28615362"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"KIT"	"exon 17 p.788-828, exon 18 p.829-860"	"missense mutation"	"gain-of-function"	"response"	"ponatinib"	"early trials"	"emerging"	"ASCO 2015 (abstr 10517)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastrointestinal_stromal_tumor"	"KIT"	"A82P9, V654A, T670I"	"missense mutation"	"gain-of-function"	"sensitivity"	"ponatinib"	"preclinical"	"emerging"	"25239608"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"RNF43"	"any"	"mutation"	"gain-of-function"	"response"	"porcupine inhibitors"	"case report"	"emerging"	"ENA 2015 (abstract C45)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"ZNRF3"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"porcupine inhibitors"	"preclinical"	"emerging"	"26023187"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thymic_lymphoma"	"TP53"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"pramlintide"	"preclinical"	"emerging"	"25409149"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"FLT3"	"F691, D835, N676, Y842"	"missense mutation"	"gain-of-function"	"resistance"	"quizartinib"	"preclinical"	"emerging"	"22504184, 23878140"	"sensitivity, resistance"	"novel FLT3 inhibitors, ponatinib, crenolanib, PKC412"	"preclinical"	"emerging"	"25847190, 25847190, 23430109, 24619500"	", resistance, sensitivity"	", sorafenib, crenolanib, PKC412"	", case report, preclinical"	", emerging"	", 22368270, 24619500"	", response"	", midostaurin"	", case report"	", emerging"	", 20733134"	", response"	", lestaurtinib"	", case report"	", emerging"	", 16857985"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"FLT3"	"ITD (Y591-597)"	"mutation"	"gain-of-function"	"response"	"quizartinib"	"early trials"	"emerging"	"ASH 2012 (abstr 673), ASH 2012 (abstr 48)"	"response"	"FLT3 inhibitors"	"early trials"	"emerging"	"16857985"	"response"	"sorafenib"	"early trials"	"emerging"	"19389879, 22368270"	"response"	"sorafenib + azacytidine"	"early trials"	"emerging"	"23613521"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MTOR"	"L1460P, S2215Y, R2505P"	"missense mutation"	"gain-of-function"	"sensitivity"	"rapamycin"	"preclinical"	"emerging"	"24631838"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"EGFR"	"L798I"	"missense mutation"	"gain-of-function"	"resistance"	"rociletinib"	"case report"	"emerging"	"27283993"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"atypical_chronic_myeloid_leukemia"	"CSF3R"	"T618I"	"missense mutation"	"gain-of-function"	"response"	"ruxolitinib"	"case report"	"emerging"	"23656643"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"JAK2"	"V617F"	"missense mutation"	"gain-of-function"	"response"	"ruxolitinib"	"early trials"	"emerging"	"22422826"	"sensitivity"	"JAK inhibitors (alone or in combination)"	"preclinical"	"emerging"	"22829971"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myelofibrosis"	"JAK2"	"V617F"	"missense mutation"	"gain-of-function"	"response"	"ruxolitinib"	"FDA-approved"	"consensus"	"FDA"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"BCR-JAK2"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"ruxolitinib"	"preclinical"	"emerging"	"22897847"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"JAK2"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"ruxolitinib"	"preclinical"	"emerging"	"22875628, 22899477"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"atypical_chronic_myeloid_leukemia"	"CSF3R"	"T615A"	"missense mutation"	"gain-of-function"	"sensitivity"	"ruxolitinib"	"preclinical"	"emerging"	"23656643"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"JAK1"	"S646F"	"missense mutation"	"gain-of-function"	"sensitivity"	"ruxolitinib"	"preclinical"	"emerging"	"22955920"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"JAK2"	"R683"	"missense mutation"	"gain-of-function"	"sensitivity"	"ruxolitinib"	"preclinical"	"emerging"	"18805579, 22955920"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"IL7R"	"237-255_indel or S185C"	"mutation"	"gain-of-function"	"sensitivity"	"ruxolitinib (in SH2B3 deleted)"	"preclinical"	"emerging"	"22897847, 22955920"	"sensitivity"	"mTOR inhibitors  (in SH2B3 deleted)"	"preclinical"	"emerging"	"22955920"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"GNA11"	"Q209L, Q209P"	"missense mutation"	"gain-of-function"	"response"	"selumetinib"	"early trials"	"emerging"	"ASCO 2013 (abstr CRA9003)"	"sensitivity"	"PI3K pathway inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"22733540, 22808163"	"sensitivity"	"vorinostat"	"preclinical"	"emerging"	"NCT01587352"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"GNAQ"	"Q209"	"missense mutation"	"gain-of-function"	"response"	"selumetinib"	"early trials"	"emerging"	"ASCO 2013 (abstr CRA9003)"	"sensitivity"	"PI3K pathway inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"22733540, 22808163"	"sensitivity"	"PKC inhibitor"	"preclinical"	"emerging"	"22653968, 22253748"	"sensitivity"	"HDAC inhibitors"	"preclinical"	"emerging"	"NCT01587352"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"PTEN"	"any"	"mutation or copy number loss"	"loss-of-function"	"response"	"sirolimus"	"early trials"	"emerging"	"ASCO 2013 (abstr 2532)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"hepatocellular_carcinoma"	"VEGFA"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"sorafenib"	"early trials"	"emerging"	"24687604"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thymic"	"KIT"	"del577-578–579"	"deletion mutation"	"gain-of-function"	"response"	"sorafenib"	"case report"	"emerging"	"20970876"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ARAF"	"S214C"	"missense mutation"	"gain-of-function"	"response"	"sorafenib"	"case report"	"emerging"	"24569458"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thymic"	"KIT"	"D820E"	"missense mutation"	"gain-of-function"	"response"	"sorafenib"	"case report"	"emerging"	"19461405"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BRAF"	"D594G, G469E"	"missense mutation"	"gain-of-function (low activity)"	"sensitivity"	"sorafenib"	"preclinical"	"emerging"	"18794803"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"hepatocellular_carcinoma"	"KRAS"	"any"	"mutation"	"gain-of-function"	"response"	"sorafenib + MEK inhibitor"	"early trials, case report"	"emerging"	"25294897"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"hepatocellular_carcinoma"	"NRAS"	"any"	"mutation"	"gain-of-function"	"response"	"sorafenib + MEK inhibitor"	"early trials, case report"	"emerging"	"25294897"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"BRAF"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"sorafenib, MEK inhibitors"	"preclinical"	"emerging"	"20526349"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"prostate"	"RAF1"	"rearrangement"	"fusion gene"	"gain-of-function"	"sensitivity"	"sorafenib, MEK inhibitors"	"preclinical"	"emerging"	"20526349"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"SF3B1"	"K700E, K666N"	"mutation"	"gain-of-function"	"sensitivity"	"spliceosome inhibitor"	"preclinical"	"emerging"	"ENA 2014 (abstr 456), ENA 2014 (abstr 575), 25424858"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_myeloid_leukemia"	"SRSF2"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"spliceosome inhibitor"	"preclinical"	"emerging"	"27135740"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lymphangioleiomyomatosis"	"TSC2"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"SRC inhibitors"	"preclinical"	"emerging"	"24691995"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"acute_lymphocytic_leukemia"	"FBXW7"	"any"	"mutation"	"loss-of-function"	"response"	"steroids in early setting"	"late trials"	"emerging"	"20861909"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thymic"	"KIT"	"H697Y"	"missense mutation"	"gain-of-function"	"sensitivity"	"sunitinib"	"preclinical"	"emerging"	"19861435"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"mantle_cell_lymphoma, chronic_lymphocytic_leukemia"	"SYK"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"SYK inhibitors"	"preclinical"	"emerging"	"16409295, 19549911"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"APC"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"tankyrase inhibitors"	"preclinical"	"emerging"	"22440753, 23539443"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"CTNNB1"	"any"	"mutation"	"gain-of-function"	"resistance"	"Tankyrase inhibitors"	"preclinical"	"emerging"	"23539443"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"MGMT"	"any"	"promoter methylation or deletion"	"loss-of-function"	"increased benefit"	"temozolomide"	"late trials"	"emerging"	"15758010"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"colorectal"	"MYC"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"temozolomide"	"preclinical"	"emerging"	"27397505"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"ATM"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"temozolomide"	"preclinical"	"emerging"	"23960094"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"glioma"	"ATR"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"temozolomide"	"preclinical"	"emerging"	"23960094"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"AKT1"	"E17K"	"missense mutation"	"gain-of-function"	"response"	"tensirolimus"	"early trials"	"emerging"	"27016228"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"TSC1"	"any"	"missense mutation"	"gain-of-function"	"response"	"tensirolimus"	"case report"	"emerging"	"27016228"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"TSC2"	"any"	"missense mutation"	"gain-of-function"	"response"	"tensirolimus"	"case report"	"emerging"	"27016228"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"NF2"	"any"	"mutation"	"loss-of-function"	"response"	"tensirolimus plus chemotherapy"	"case report"	"emerging"	"25878190"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"HRAS"	"any"	"mutation"	"gain-of-function"	"sensitivity"	"tipifarnib"	"early trials"	"emerging"	"NCT02383927"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"MAP2K1"	"Q56P"	"missense mutation"	"gain-of-function"	"sensitivity"	"trametinib"	"preclinical"	"emerging"	"26582713"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"chronic_myeloid_leukemia"	"PRKCH"	"amplification"	"copy number gain"	"gain-of-function"	"sensitivity"	"trametinib (plus imatinib in BCR-ABL)"	"preclinical"	"emerging"	"25186176"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BRAF"	"V600K"	"missense mutation"	"gain-of-function"	"response"	"trametinib, dabrafenib + trametinib, vemurafenib + cobimetinib"	"FDA-approved"	"consensus"	"FDA"	"response"	"vemurafenib"	"late trials"	"emerging"	"22356324"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BRAF"	"L597R"	"missense mutation"	"gain-of-function"	"response"	"trametinib, MEK inhibitors"	"case report"	"emerging"	"22805292, 22798288"	"response"	"BRAF inhibitors"	"case report"	"emerging"	"23715574"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"gastric"	"ERBB2"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"trastuzumab"	"FDA-approved"	"consensus"	"FDA"	"response"	"afatinib"	"case report"	"emerging"	"AACR 2014 (abstr CT228)"	"response"	"pertuzumab"	"early trials"	"emerging"	"24960402"	"response"	"lapatinib (plus chemotherapy)"	"early trials"	"emerging"	"25694417, NCT02015169"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"ERBB2"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"trastuzumab"	"early trials"	"emerging"	"20003286, 12525520"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast cancer"	"ARID1A"	"mut"	"mutation or copy number loss"	"loss-of-function"	"resistance"	"trastuzumab (ANXA1 high)"	"early trials"	"emerging"	"27172896"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"endometrial"	"ERBB2"	"amplification"	"copy number gain"	"gain-of-function"	"no response"	"trastuzumab alone"	"early trials"	"emerging"	"19840887"	"sensitivity"	"trastuzumab + lapatinib"	"preclinical"	"emerging"	"25294905"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"HGF"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"trastuzumab in HER2-ampl"	"early trials"	"emerging"	"22850551"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"MET"	"amplification"	"copy number gain"	"gain-of-function"	"resistance"	"trastuzumab in HER2-amplified"	"early trials"	"emerging"	"22850551"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"ERBB2"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"trastuzumab-based chemotherapy"	"case report"	"emerging"	"21380780"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ERBB2"	"G776L"	"missense mutation"	"gain-of-function"	"response"	"trastuzumab-based therapy"	"case report"	"emerging"	"16775247"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung_adeno"	"ERBB2"	"proximal exon 20 p.775-881"	"insertion mutation"	"gain-of-function"	"response"	"trastuzumab, lapatinib, afatinib, neratinib"	"early trials"	"emerging"	"26598547, ASCO 2017 (abstr 9071)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB2"	"D769Y, D769H, R896C"	"missense mutation"	"gain-of-function"	"sensitivity"	"trastuzumab, lapatinib, neratinib"	"preclinical"	"emerging"	"23220880"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"biliary_tract"	"ERBB2"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"trastuzumab, lapatinib, pertuzumab"	"early trials"	"emerging"	"26022204"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"breast"	"ERBB2"	"amplification"	"copy number gain"	"gain-of-function"	"response"	"trastuzumab, lapatinib, pertuzumab, ado-trastuzumab emtansine"	"FDA-approved"	"consensus"	"FDA"	"response"	"neratinib, afatinib"	"late trials"	"emerging"	"20142587, 22418700, 23632474"	"response"	"trastuzumab + HSP90 inhibitors"	"early trials"	"emerging"	"21558407"	"response"	"trastuzumab + everolimus + chemotherapy"	"early trials"	"emerging"	"21107682, 20975068"	"sensitivity"	"HER2 inhibitors + CDK4/6 inhibitors"	"preclinical"	"emerging"	"26977878"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"ERBB3"	"Q809R"	"missense mutation"	"gain-of-function"	"sensitivity"	"trastuzumab, lapatinib, PI3K pathway inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"23680147"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"ERBB3"	"P262H, G284R"	"missense mutation"	"gain-of-function"	"sensitivity"	"trastuzumab, pertuzumab, lapatinib, anti-HER3 mAbs, PI3K pathway inhibitors + MEK inhibitors"	"preclinical"	"emerging"	"23680147"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thyroid"	"RET"	"codon 618, 620, 634, 768, 791, 891, 918, C634W, M918T"	"missense mutation"	"gain-of-function"	"response"	"vandetanib"	"FDA-approved"	"consensus"	"20065189, 22025146"	", sensitivity"	", cabozantinib, sunitinib"	", preclinical"	", emerging"	", 21470995"	", sensitivity"	", RET inhibitors"	", preclinical"	", emerging"	", 23056499"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"KDR"	"A1065T"	"missense mutation"	"gain-of-function"	"sensitivity"	"VEGFR inhibitors"	"preclinical"	"emerging"	"24569783"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"MAP2K1"	"K57E, E203K, Q56P"	"missense mutation"	"gain-of-function"	"resistance"	"vemurafenib"	"case report"	"emerging"	"23569304"	", resistance"	", BRAF inhibitors, MEK inhibitors"	", preclinical"	", emerging"	", 19915144"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"hairy_cell_leukemia"	"BRAF"	"V600E"	"missense mutation"	"gain-of-function"	"response"	"vemurafenib"	"case report"	"emerging"	"22621641"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BRAF"	"V600D,V600K,V600M,V600G,V600R"	"missense mutation"	"gain-of-function"	"response"	"vemurafenib"	"NCCN guidelines"	"consensus"	"NCCN"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"myeloma"	"BRAF"	"V600E"	"missense mutation"	"gain-of-function"	"response"	"vemurafenib"	"case report"	"emerging"	"23612012"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"thyroid"	"BRAF"	"V600E"	"missense mutation"	"gain-of-function"	"response"	"vemurafenib, dabrafenib"	"early trials"	"emerging"	"22608338, 20818844, 23489023, 27460442"	"response"	"MEK inhibitors"	"early trials"	"emerging"	"22241789"	"response"	"MEK-inhibitor enhanced radioiodine uptake"	"early trials"	"emerging"	"23406027"	"response"	"BRAF inhibitors + MEK inhibitors"	"early trials"	"emerging"	"ASCO 2013 (abstr 9029)"	"response"	"pan-RAF inhibitors"	"early trials"	"emerging"	"AACR 2016 (abstr CT005)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"melanoma"	"BRAF"	"V600E"	"missense mutation"	"gain-of-function"	"response"	"vemurafenib, dabrafenib, trametinib, dabrafenib + trametinib, vemurafenib + cobimetinib"	"FDA-approved"	"consensus"	"FDA"	"response"	"pan-RAF inhibitors"	"early trials"	"emerging"	"ESMO 2015 (abstract 300), AACR 2016 (abstr CT005), AACR 2017 (abstr  CT002)"	"sensitivity"	"BRAF inhibitors + PI3K pathway inhibitors"	"preclinical"	"emerging"	"22389471, 21156289"	"sensitivity"	"BRAF inhibitors + HSP90 inhibitors"	"preclinical"	"emerging"	"22351686"	"sensitivity"	"BRAF inhibitors + CDK2/4 inhibitors"	"preclinical"	"emerging"	"22997239"	"sensitivity"	"ERK inhibitors"	"preclinical"	"emerging"	"23614898, 22997239"	""	""	""	""	""	""	""	""	""	""
"basal_cell_carcinoma"	"SMO"	"G497W, D473Y"	"missense mutation"	"gain-of-function"	"resistance"	"vismodegib"	"case report"	"emerging"	"25306392"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"medulloblastoma"	"SMO"	"D473H"	"missense mutation"	"gain-of-function"	"resistance"	"vismodegib"	"case report"	"emerging"	"19726788, 25759019"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"lung"	"SMO"	"P641A"	"missense mutation"	"gain-of-function"	"response"	"vismodegib"	"case report"	"emerging"	"ASCO 2017 (abstr 9062)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"basal_cell_carcinoma"	"PTCH1"	"any"	"mutation"	"loss-of-function"	"response"	"vismodegib"	"FDA-approved"	"emerging"	"19726763"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"medulloblastoma"	"PTCH1"	"any"	"mutation"	"loss-of-function"	"response"	"vismodegib"	"FDA-approved"	"emerging"	"19726761"	"sensitivity"	"foretinib"	"preclinical"	"emerging"	"25391241"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"BRCA1"	"any"	"mutation"	"loss-of-function"	"response"	"WEE1 inhibitors"	"case report"	"emerging"	"25964244"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"head_neck"	"TP53"	"any"	"mutation"	"loss-of-function"	"sensitivity"	"WEE1 inhibitors"	"preclinical"	"emerging"	"25125259"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"cancer_unspecified"	"SETD2"	"any"	"mutation or copy number loss"	"loss-of-function"	"sensitivity"	"WEE1 inhibitors"	"preclinical"	"emerging"	"ENA 2014 (abstr 211)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
"ovarian"	"TP53"	"any"	"mutation"	"gain-of-function"	"response"	"WEE1 inhibitors + carboplatin"	"early trials"	"emerging"	"ASCO2015 (abstr 2507)"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""
